Why the study?
Does tirofiban prevent complications during premature interruption of dual antiplatelet therapy in patients with recent drug eluting stent implantation undergoing major surgery?
Does tirofiban prevent complications during premature interruption of dual antiplatelet therapy in patients with recent drug eluting stent implantation undergoing major surgery?
Tirofiban may serve as a safe bridging strategy for patients with recent drug-eluting stents who require premature interruption of dual antiplatelet therapy for major surgery.
Answers are grounded in this paper and cite their sources.
May support tirofiban bridging during DAPT interruption for surgery in recent DES; leaves open randomized confirmation.
We describe four cases of patients with multiple coronary drug eluting stent implantation who underwent major surgery (cardiac and noncardiac) early after stent implantation and needed premature interruption of dual antiplatelet therapy. The transitory withdrawal of oral antiplatelet therapy was accomplished without complications with the use of an IIb/IIIa glycoprotein inhibitor (Tirofiban).
No takes yet. Share an insight, caveat, or question.
DʼUrbano et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: